CASP3 and breast cancer: Treatment with apigenin significantly decreased BC cell growth in a dose-dependent manner (Fig. 4a) and activated the effector caspase-3 and cleavage of poly-(ADP-ribose) polymerase (PARP) in BC cells (Fig. 4b).